CrossBridge Bio is pioneering advancements in Antibody-Drug Conjugates (ADCs) through its innovative technologies, particularly focusing on the development of stable dual linker payload systems. Central to their approach is the proprietary EGCit (GluGlyCit) enzymatically cleavable linker, which offers enhanced stability compared to traditional linkers like ValCit. This unique linker is designed to prevent premature payload release, thereby minimizing adverse effects while ensuring effective drug delivery directly within targeted cancer cells. Additionally, the increased hydrophilicity of the EGCit linker helps to reduce unintended tissue uptake and rapid clearance from the body, optimizing the therapeutic potential of the ADCs.

Another significant aspect of CrossBridge Bio's technology is the enzymatic conjugation of branched linkers using microbial transglutaminase (mTG). This method allows for precise integration of multi-arm linkers into human IgG1 antibodies, enabling the creation of uniform ADCs with controlled Drug-to-Antibody Ratios (DAR). This innovation facilitates the development of dual-payload ADCs, which can provide synergistic therapeutic effects while maintaining the production simplicity of single-payload ADCs. By combining various antibodies with diverse payload mechanisms, CrossBridge Bio aims to deliver a range of ADC products that exhibit optimal pharmacological properties and safety profiles, ultimately revolutionizing cancer treatment.

United States

CrossBridge Bio is a biotechnology company focused on developing innovative ADC therapeutics using our proprietary stable dual-linker payload technology.

CrossBridge Bio

Company Details